{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:52:49Z","timestamp":1781632369145,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cannabis Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Persistent, multimodal cancer pain remains a challenge, particularly in long-term survivors facing treatment-related complications. The management of high-dose opioid dependence concurrent with chronic, multi-drug resistant (MDR) periprosthetic infection presents a critical unmet need. This case reports the potential use and sustained efficacy of medical cannabis monotherapy, highlighting an unexpected temporal association with the resolution of inflammatory and infectious symptoms in a highly complex oncologic setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 27-year-old male, a long-term survivor of high-risk Ewing Sarcoma of the proximal tibia, presented with intractable mixed pain (VAS 9\u201310) secondary to chronic, recurrent MDR periprosthetic osteomyelitis and multiple surgical revisions (2013\u20132024). Despite continuous use of high-dose opioids (up to 120\u00a0mg\/day morphine equivalents), pain levels remained moderate-to-severe (VAS 6\u20137) and functional status was poor. The patient had previously found temporary relief with self-administered cannabis. In January 2025, after refusing limb amputation, supervised medical cannabis therapy (Bedrocan\n                      <jats:sup>\u00ae<\/jats:sup>\n                      , 22% THC, 1% CBD, 1\u00a0g\/day) was initiated. Pain levels gradually stabilized at VAS 2\u20133, coinciding with complete opioid discontinuation within four weeks. Over nine months of follow-up, the patient maintained full autonomy and an active lifestyle. Notably, sustained cannabis monotherapy was associated with the complete closure of the chronic draining fistula and a reduction in systemic inflammatory markers (CRP from 9.6 to 2.3\u00a0mg\/dL). No significant adverse effects were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case suggests that THC-rich medical cannabis may represent a feasible strategy for achieving opioid-free analgesia in selected patients with refractory oncologic pain. While causality cannot be established from a single observation, the correlation between cannabis initiation and the resolution of severe chronic inflammatory and infectious symptoms is intriguing and suggests a potential pleiotropic role extending beyond traditional pain management. While these findings align with emerging evidence highlighting the potent immunomodulatory and anti-inflammatory properties of cannabinoids, they contrast with some recent neutral meta-analyses in broader populations, an this would justify warrant urgent controlled investigation into the potential mechanisms of cannabinoids in complex inflammatory pain states and their role as a possible adjunct in managing long-term oncological complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42238-026-00388-x","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T01:36:49Z","timestamp":1769132209000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ewing sarcoma-related pain: potential role of medical cannabis monotherapy in symptom management \u2013 a case report"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6941-2752","authenticated-orcid":false,"given":"Cesare","family":"De Virgilio Suglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice Antonio","family":"Spaccavento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Turco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"De Trizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Giannuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4194-0210","authenticated-orcid":false,"given":"Silvio","family":"Tafuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"388_CR1","doi-asserted-by":"publisher","unstructured":"Abrams DI, Cannabis. Cannabinoids and Cannabis-Based medicines in cancer care. Integr Cancer Ther. 2022;21:15347354221081772. https:\/\/doi.org\/10.1177\/15347354221081772. PMID: 35225051; PMCID: PMC8882944.","DOI":"10.1177\/15347354221081772"},{"issue":"13","key":"388_CR2","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1200\/JCO.23.02596","volume":"42","author":"IM Braun","year":"2024","unstructured":"Braun IM, Bohlke K, Abrams DI, Anderson H, Balneaves LG, Bar-Sela G, Bowles DW, Chai PR, Damani A, Gupta A, Hallmeyer S, Subbiah IM, Twelves C, Wallace MS, Roeland EJ. Cannabis and cannabinoids in adults with cancer: ASCO guideline. J Clin Oncol. 2024;42(13):1575\u201393. Epub 2024 Mar 13. PMID: 38478773; PMCID: PMC11730458.","journal-title":"J Clin Oncol"},{"key":"388_CR3","doi-asserted-by":"publisher","unstructured":"Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G, European Palliative Care Research Collaborative (EPCRC). ; European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58-68. https:\/\/doi.org\/10.1016\/S1470-2045(12)70040-2. PMID: 22300860.","DOI":"10.1016\/S1470-2045(12)70040-2"},{"key":"388_CR4","doi-asserted-by":"publisher","unstructured":"Castle RD, Marzolf J, Morris M, Bushell WC. Meta-analysis of medical cannabis outcomes and associations with cancer. Front Oncol. 2025;15:1490621. https:\/\/doi.org\/10.3389\/fonc.2025.1490621. PMID: 40303989; PMCID: PMC12037605.","DOI":"10.3389\/fonc.2025.1490621"},{"key":"388_CR5","doi-asserted-by":"publisher","unstructured":"Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, Ripamonti CI, ESMO Guidelines Committee. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv166-iv191. https:\/\/doi.org\/10.1093\/annonc\/mdy152. PMID: 30052758.","DOI":"10.1093\/annonc\/mdy152"},{"key":"388_CR6","doi-asserted-by":"publisher","unstructured":"Fisher E, Moore RA, Fogarty AE, Finn DP, Finnerup NB, Gilron I, Haroutounian S, Krane E, Rice ASC, Rowbotham M, Wallace M, Eccleston C. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain. 2021;162(Suppl 1):S45-S66. https:\/\/doi.org\/10.1097\/j.pain.0000000000001929. PMID: 32804836.","DOI":"10.1097\/j.pain.0000000000001929"},{"issue":"17","key":"388_CR7","doi-asserted-by":"publisher","first-page":"5036","DOI":"10.3390\/jcm11175036","volume":"11","author":"A Gorzo","year":"2022","unstructured":"Gorzo A, Hava\u0219i A, Sp\u00eenu \u0218, Oprea A, Burz C, Sur D. Practical considerations for the use of cannabis in cancer pain Management-What a medical oncologist should know. J Clin Med. 2022;11(17):5036. https:\/\/doi.org\/10.3390\/jcm11175036. PMID: 36078963; PMCID: PMC9457511.","journal-title":"J Clin Med"},{"issue":"6","key":"388_CR8","doi-asserted-by":"publisher","first-page":"CD014915","DOI":"10.1002\/14651858.CD014915.pub2","volume":"6","author":"W H\u00e4user","year":"2023","unstructured":"H\u00e4user W, Welsch P, Radbruch L, Fisher E, Bell RF, Moore RA. Cannabis-based medicines and medical cannabis for adults with cancer pain. Cochrane Database Syst Rev. 2023;6(6):CD014915. https:\/\/doi.org\/10.1002\/14651858.CD014915.pub2. PMID: 37283486; PMCID: PMC10241005.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"388_CR9","doi-asserted-by":"publisher","first-page":"e28801","DOI":"10.1002\/pbc.28801","volume":"68","author":"M Heinemann","year":"2021","unstructured":"Heinemann M, Hoffmann C, Hardes J, Guder W, Streitb\u00fcrger A, G\u00f6tte M, Welz TL, J\u00fcrgens H, Ranft A, Vieth V, Weckesser M, Sch\u00e4fers M, Stegger L, Dirksen U. Pain in survivors of ewing sarcoma: Prevalence, associated factors and prediction of recurrence. Pediatr Blood Cancer. 2021;68(3):e28801. https:\/\/doi.org\/10.1002\/pbc.28801. Epub 2020 Nov 12. PMID: 33179838.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"388_CR10","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3390\/cancers13061202","volume":"13","author":"AC Hesla","year":"2021","unstructured":"Hesla AC, Papakonstantinou A, Tsagkozis P. Current status of management and outcome for patients with ewing sarcoma. Cancers (Basel). 2021;13(6):1202. https:\/\/doi.org\/10.3390\/cancers13061202. PMID: 33801953; PMCID: PMC7998375.","journal-title":"Cancers (Basel)"},{"key":"388_CR11","doi-asserted-by":"publisher","unstructured":"Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis. J Pain Symptom Manage. 2016;51(6):1070\u20131090.e9. https:\/\/doi.org\/10.1016\/j.jpainsymman.2015.12.340. Epub 2016 Apr 23. PMID: 27112310.","DOI":"10.1016\/j.jpainsymman.2015.12.340"},{"key":"388_CR12","doi-asserted-by":"publisher","unstructured":"Lawson McLean A, Kahr J, R\u00e9gis J, Kamp MA, Senft C. Epidemiology of resistant cancer pain: Prevalence, clinical Burden, and treatment gaps. Stereotact Funct Neurosurg. 2025:1\u201313. https:\/\/doi.org\/10.1159\/000547446. Epub ahead of print. PMID: 40669453.","DOI":"10.1159\/000547446"},{"issue":"2","key":"388_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jpainsymman.2017.09.001","volume":"55","author":"AH Lichtman","year":"2018","unstructured":"Lichtman AH, Lux EA, McQuade R, Rossetti S, Sanchez R, Sun W, Wright S, Kornyeyeva E, Fallon MT. Results of a Double-Blind, Randomized, Placebo-Controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manage. 2018;55(2):179\u2013e1881. Epub 2017 Sep 18. PMID: 28923526.","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"388_CR14","doi-asserted-by":"publisher","first-page":"e31551","DOI":"10.1002\/pbc.31551","volume":"72","author":"R Luksch","year":"2025","unstructured":"Luksch R, Palmerini E, Milano GM, Paioli A, Asaftei S, Barretta F, Puma N, Cesari M, Tirtei E, Podda M, Pierobon M, Manzitti C, Ferraresi V, Tamburini A, Bertulli R, Di Pinto D, Mascarin M, Grignani G, Coccoli L, Rabusin M, De Leonardis F, Gambarotti M, Parafioriti A, Cammelli S, Vennarini S, Ferrari S, Donati DM, Bastoni S, Massimino M, Fagioli F, Ibrahim T. Intensified induction therapy for newly Diagnosed, localized skeletal ewing sarcoma (ISG\/AIEOP EW-1): A Randomized, Open-Label, phase 3, Non-Inferiority trial. Pediatr Blood Cancer. 2025;72(4):e31551. https:\/\/doi.org\/10.1002\/pbc.31551. Epub 2025 Jan 20. PMID: 39833645.","journal-title":"Pediatr Blood Cancer"},{"issue":"30","key":"388_CR15","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1200\/JCO.2012.41.7238","volume":"30","author":"DR Pachman","year":"2012","unstructured":"Pachman DR, Barton DL, Swetz KM, Loprinzi CL. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol. 2012;30(30):3687\u201396. https:\/\/doi.org\/10.1200\/JCO.2012.41.7238. Epub 2012 Sep 24. PMID: 23008320.","journal-title":"J Clin Oncol"},{"key":"388_CR16","doi-asserted-by":"publisher","unstructured":"Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, McQuade R, Wright S, Fallon MT. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438\u2009\u2013\u200949. https:\/\/doi.org\/10.1016\/j.jpain.2012.01.003. Epub 2012 Apr 5. PMID: 22483680.","DOI":"10.1016\/j.jpain.2012.01.003"},{"key":"388_CR17","doi-asserted-by":"publisher","unstructured":"Schmidt BL. The neurobiology of cancer pain. Neuroscientist. 2014;20(5):546\u2009\u2013\u200962. https:\/\/doi.org\/10.1177\/1073858414525828. Epub 2014 Mar 24. PMID: 24664352; PMCID: PMC4161642.","DOI":"10.1177\/1073858414525828"},{"key":"388_CR18","doi-asserted-by":"publisher","first-page":"119993","DOI":"10.1016\/j.lfs.2021.119993","volume":"285","author":"AM Shoeib","year":"2021","unstructured":"Shoeib AM, Yarbrough AL, Ford BM, Franks LN, Urbaniak A, Hensley LL, Benson LN, Mu S, Radominska-Pandya A, Prather PL. Characterization of cannabinoid receptors expressed in ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development. Life Sci. 2021;285:119993. Epub 2021 Sep 28. PMID: 34592231; PMCID: PMC10395316.","journal-title":"Life Sci"},{"key":"388_CR19","doi-asserted-by":"publisher","unstructured":"Wang L, Hong PJ, May C, Rehman Y, Oparin Y, Hong CJ, Hong BY, AminiLari M, Gallo L, Kaushal A, Craigie S, Couban RJ, Kum E, Shanthanna H, Price I, Upadhye S, Ware MA, Campbell F, Buchbinder R, Agoritsas T, Busse JW. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ. 2021;374:n1034. https:\/\/doi.org\/10.1136\/bmj.n1034. PMID: 34497047.","DOI":"10.1136\/bmj.n1034"},{"issue":"7","key":"388_CR20","doi-asserted-by":"publisher","first-page":"CD012592","DOI":"10.1002\/14651858.CD012592.pub2","volume":"7","author":"PJ Wiffen","year":"2017","unstructured":"Wiffen PJ, Wee B, Derry S, Bell RF, Moore RA. Opioids for cancer pain - an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;7(7):CD012592. https:\/\/doi.org\/10.1002\/14651858.CD012592.pub2. PMID: 28683172; PMCID: PMC6483487.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Journal of Cannabis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42238-026-00388-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-026-00388-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-026-00388-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:59:05Z","timestamp":1781629145000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42238-026-00388-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["388"],"URL":"https:\/\/doi.org\/10.1186\/s42238-026-00388-x","relation":{},"ISSN":["2522-5782"],"issn-type":[{"value":"2522-5782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient provided written consent both to undergo medical cannabis therapy and to the publication of the study results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient provided written consent both to undergo medical cannabis therapy and to the publication of the study results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}